Half-year report · Q2

Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥1.82T2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥3.56T2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥1.78T2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥27.2bn2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥20.6bn2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥35.1bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥64.6bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥29.3bn2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥39.8bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥32.8bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥21.7bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥41.5bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥17.2bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥27.6bn2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥22.5bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥1.88Tat 2024-09-30Cons.Assets
Total assets¥1.80Tat 2024-03-31Cons.Assets
Total assets¥1.82Tat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥1.12Tat 2024-09-30Cons.Liabilities
Total liabilities¥1.06Tat 2024-03-31Cons.Liabilities
Net assets / equity¥757.7bnat 2024-09-30Cons.Net assets
Net assets / equity¥736.6bnat 2024-03-31Cons.Net assets
Net assets / equity¥714.6bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥251.1bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥230.2bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥249.0bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥228.1bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥207.0bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥193.6bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥41.8bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥61.8bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥31.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥6.5bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥7.8bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥10.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥14.4bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥25.2bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥12.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥103.942024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥195.832023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥80.482023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio32.9%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio33.4%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio32.1%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥2.0bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥2.0bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30¥161m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥58.6bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥58.6bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥1m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥1.2bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥600.4bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥600.2bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥201m
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥14.0bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥1.17T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥1.17T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥1.8bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥11.9bn
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2024-09-30¥1.83T
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2024-09-30¥1.82T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2024-04-01 → 2024-09-30¥2.0bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2024-09-30¥27.0bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥1.2bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥1.2bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥37m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥56.8bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥56.8bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.5bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥583.4bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥583.3bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥146m
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥13.8bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥1.14T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥1.14T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1.1bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥5.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥1.78T
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥1.78T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥1.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥20.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 513
ItemContextValueUnit
Increase decrease in net defined benefit liability ope cfCurrentYTDDuration-105000000JPY
Decrease increase in notes and accounts receivable trade ope cfPrior1YTDDuration-48985000000JPY
Decrease increase in notes and accounts receivable trade ope cfCurrentYTDDuration-13703000000JPY
Decrease increase in inventories ope cfPrior1YTDDuration-5392000000JPY
Decrease increase in inventories ope cfCurrentYTDDuration-25556000000JPY
Increase decrease in notes and accounts payable trade ope cfPrior1YTDDuration52485000000JPY
Increase decrease in notes and accounts payable trade ope cfCurrentYTDDuration56666000000JPY
Other net ope cfPrior1YTDDuration-753000000JPY
Other net ope cfCurrentYTDDuration-13417000000JPY
Subtotal ope cfPrior1YTDDuration38373000000JPY
Subtotal ope cfCurrentYTDDuration51660000000JPY
Interest and dividends income received ope cf inv cfPrior1YTDDuration3798000000JPY
Interest and dividends income received ope cf inv cfCurrentYTDDuration2608000000JPY
Interest expenses paid ope cf fin cfPrior1YTDDuration-1000000JPY
Interest expenses paid ope cf fin cfCurrentYTDDuration-2000000JPY
Proceeds from compensation ope cfPrior1YTDDuration2768000000JPY
Proceeds from compensation ope cfCurrentYTDDuration-JPY
Payments for loss on disaster ope cfPrior1YTDDuration-JPY
Payments for loss on disaster ope cfCurrentYTDDuration-406000000JPY
Income taxes paid ope cfPrior1YTDDuration-13723000000JPY
Income taxes paid ope cfCurrentYTDDuration-12027000000JPY
Net cash provided by used in operating activitiesPrior1YTDDuration31215000000JPY
Net cash provided by used in operating activitiesCurrentYTDDuration41832000000JPY
Purchase of property plant and equipment inv cfPrior1YTDDuration-10730000000JPY
Purchase of property plant and equipment inv cfCurrentYTDDuration-7070000000JPY
Proceeds from sales of property plant and equipment inv cfPrior1YTDDuration3000000JPY
Proceeds from sales of property plant and equipment inv cfCurrentYTDDuration2000000JPY
Purchase of investment securities inv cfPrior1YTDDuration-136000000JPY
Purchase of investment securities inv cfCurrentYTDDuration-356000000JPY
Proceeds from sales and redemption of investment securities inv cfPrior1YTDDuration1192000000JPY
Proceeds from sales and redemption of investment securities inv cfCurrentYTDDuration5943000000JPY
Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cfPrior1YTDDuration-JPY
Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cfCurrentYTDDuration-3403000000JPY
Other net inv cfPrior1YTDDuration-1129000000JPY
Other net inv cfCurrentYTDDuration-1635000000JPY
Net cash provided by used in investment activitiesPrior1YTDDuration-10800000000JPY
Net cash provided by used in investment activitiesCurrentYTDDuration-6520000000JPY
Purchase of treasury stock fin cfPrior1YTDDuration-5983000000JPY
Purchase of treasury stock fin cfCurrentYTDDuration-5068000000JPY
Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation fin cfPrior1YTDDuration-JPY
Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation fin cfCurrentYTDDuration-1503000000JPY
Cash dividends paid fin cfPrior1YTDDuration-4829000000JPY
Cash dividends paid fin cfCurrentYTDDuration-6300000000JPY
Dividends paid to non controlling interests fin cfPrior1YTDDuration-1270000000JPY
Dividends paid to non controlling interests fin cfCurrentYTDDuration-1518000000JPY
Other net fin cfPrior1YTDDuration-654000000JPY
Other net fin cfCurrentYTDDuration14000000JPY
Net cash provided by used in financing activitiesPrior1YTDDuration-12738000000JPY
Net cash provided by used in financing activitiesCurrentYTDDuration-14376000000JPY
Effect of exchange rate change on cash and cash equivalentsPrior1YTDDuration0JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass